GuidelineESMO open2025
ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma.
Guideline in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07565857 (SIGNAL GEC-101), which is not on this map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SIGNAL GEC-101: Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of esophageal cancer (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Predictive value of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced/recurrent endometrial cancer: a meta-analysis.World journal of surgical oncology · 2026Pooled it
- First-line systemic therapy for advanced or metastatic esophageal squamous cell carcinoma: clinical implications for treatment selection after KEYNOTE-590, CheckMate 648, and RATIONALE-306.Clinical journal of gastroenterology · 2026Review
- Cancer treatment alters mutant selection in normal esophagus.Nature genetics · 2026Article
- Cancer treatment alters the selection of pre-existing somatic mutations in normal esophagus.Nature genetics · 2026Article
- Neoadjuvant Chemoimmunotherapy versus Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis.Annals of surgical oncology · 2026Review
- Tumor-associated calcium signal transducer 2 expression as a promising therapeutic target in esophageal squamous cell carcinoma: a combined the Cancer Genome Atlas and an institutional cohort.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Patterns of Recurrence in Adenocarcinoma of the Esophagogastric Junction: ERECS Trial Post Hoc Analysis.Annals of surgical oncology · 2026Article
- Sex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis.ESMO gastrointestinal oncology · 2026Review
- Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands.ESMO gastrointestinal oncology · 2026Article
- [Personalized systemic treatment of metastatic esophageal cancer].Chirurgie (Heidelberg, Germany) · 2026Review
- Exploring the origins of esophagogastric junction cancer through omics: A focus on the Siewert II subclassification.Surgery today · 2026Review
- Perioperative FLOT chemotherapy for locally advanced esophageal adenocarcinoma: from ESOPEC to daily practice-a retrospective cohort study.Journal of thoracic disease · 2026Article
- Beyond Pathological Complete Response: Long-term Outcomes in Esophageal and Esophagogastric Junction Adenocarcinoma After Multimodal Therapy-A Systematic Review and Individual Patient-Data Meta-Analysis.Annals of surgical oncology · 2026Article
- Development and validation of a clinically interpretable risk scoring system for predicting one-year all-cause mortality in esophageal cancer: a population-based study.Journal of thoracic disease · 2026Article
- Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies.ESMO gastrointestinal oncology · 2026Review
- Early Outcomes of Transhiatal Esophagectomy: Experience From an Oncology Center in Nepal.Cureus · 2026Article
- Early- versus late-onset gastroesophageal cancer: real-world outcomes from a 13-year central European cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Treatment and survival of patients with esophageal and gastric cancer in the Netherlands and Belgium: A population-based comparison.International journal of cancer · 2026Article
- [Long-term results of the ESOPEC trial: perioperative chemotherapy versus neoadjuvant chemoradiotherapy for resectable adenocarcinoma of the esophagus].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.